|
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. |
|
|
Stock and Other Ownership Interests - PEGASCY |
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merieux Nutrisciences; Oncovir |
Consulting or Advisory Role - AMGEN; AstraZeneca; Bayer; Bioncotech; Boehringer Ingelheim; CERENIS THERAPEUTICS; Eisai; Gritstone Bio; ImCheck therapeutics; Innate Pharma; Lytix Biopharma; Merck Serono; Molecular Partners; MSD; NOVARTIS; OSE Immunotherapeutics; Partner Therapeutics; Pfizer; Pfizer; Pierre Fabre; Redx Pharma; Roche; Sanofi; SERVIER; Sotio; Symphogen |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Roche |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MERUS (Inst); MSD (Inst); Transgene (Inst) |
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche |
Other Relationship - PEGASCY |
|
Philippe Alexandre Cassier |
Honoraria - Amgen; AstraZeneca; Blueprint Medicines; Novartis; Roche/Genentech |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Netris Pharma; Novartis; Roche |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche |
Speakers' Bureau - Amgen; Taiho Pharmaceutical |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche |
Consulting or Advisory Role - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Pfizer (Inst) |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche |
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Research Funding - Netherlands Cancer Institute (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Libbs |
Research Funding - Bristol-Myers Squibb; Mabxience; Merck Sharp & Dohme |
|
|
Stock and Other Ownership Interests - PrimeVax |
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - ARQULE; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; MSD; Pfizer; Sanofi; SERVIER |
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda |
|
|
Consulting or Advisory Role - AstraZeneca; Roche |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Merck; Novartis; Pfizer |
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Pfizer (Inst) |
Expert Testimony - Boehringer Ingelheim |
|
|
Consulting or Advisory Role - Merck |
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst) |
|
|
Employment - Merck Sharp & Dohme |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech |
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); MSD Oncology (Inst) |